Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.
Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.
复制标题
DOI：
--
复制
发表时间：
1999-11
期刊：
影响因子：
11.2
通讯作者：
Guang Yang;L. Truong;T. Wheeler;T. Thompson
中科院分区：
文献类型：
--
作者：
Guang Yang;L. Truong;T. Wheeler;T. Thompson
我们证明了先前在体外和体内转移性小鼠和人前列腺癌细胞中窖蛋白-1表达升高。在这项研究中，我们分析了其对临床局限的人前列腺癌进展的预后价值。免疫组化染色与小窝蛋白-1特异性抗体进行常规处理的石蜡切片从189根治性前列腺切除术标本。Caveolin-1免疫反应性与患者的年龄、种族、术前前列腺特异性抗原、临床分期和病理特征（包括Gleason评分、前列腺外扩展、手术切缘状态和术后疾病进展时间）相关。在189例癌症中，47例（25%）检测到caveolin-1免疫染色阳性，并与Gleason评分、手术切缘阳性以及淋巴结受累呈正相关（P分别为0.0071、0.0267和0.0399）。在淋巴结阴性的癌症中（n = 162），小窝蛋白-1免疫反应性预测手术后疾病进展的时间较短（P = 0.0033，单变量分析）。包括小窝蛋白-1和其他预后病理标志物的多变量分析将阳性小窝蛋白-1免疫染色确定为疾病进展时间的独立预测因子（P = 0.0186）。因此，我们的研究确立了小窝蛋白-1作为临床局限的人前列腺癌的新的预后标志物。
We demonstrated previously elevated caveolin-1 expression in metastatic mouse and human prostate cancer cells both in vitro and in vivo. In this study, we analyzed its prognostic value for progression of clinically confined human prostate cancer. Immunohistochemical staining with a caveolin-1-specific antibody was performed on routinely processed paraffin sections from 189 radical prostatectomy specimens. Caveolin-1 immunoreactivity was evaluated in association with patients' age, race, preoperative prostate-specific antigen, clinical stage, and pathological features including Gleason score, extraprostatic extension, status of surgical margins, and time to disease progression after surgery. Positive caveolin-1 immunostaining was detected in 47 of the 189 cancers (25%) and correlated positively with Gleason score, positive surgical margin, as well as lymph node involvement (P = 0.0071, 0.0267, and 0.0399, respectively). In lymph node-negative cancers (n = 162), caveolin-1 immunoreactivity predicts a shorter time to disease progression after surgery (P = 0.0033, univariate analysis). Multivariate analyses that included caveolin-1 and other prognostic pathological markers identified positive caveolin-1 immunostaining as an independent predictor for time to disease progression (P = 0.0186). Thus, our study establishes caveolin-1 as a novel prognostic marker for clinically confined human prostate cancer.